文献速递瓣膜病与结构性心脏病

轻中度主动脉瓣狭窄进展与脂蛋白(a)及氧化磷脂水平呈线性关联

Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2018-01-01

该研究为ASTRONOMER随机临床试验的二次分析,纳入220例轻中度钙化性主动脉瓣狭窄患者,中位随访3.5年。结果显示基线脂蛋白(a)、OxPL-apoB和OxPL-apo(a)水平与主动脉瓣狭窄进展速率呈线性关联,在年轻患者中更明显,多变量调整后仍显著。

要点

  • 脂蛋白(a)每升高10 mg/dL,瓣膜狭窄进展风险增加10%(OR 1.10)。
  • 年轻患者中脂蛋白(a)每升高10 mg/dL,进展风险增加19%(OR 1.19)。
  • 建议对轻中度主动脉瓣狭窄患者检测脂蛋白(a)以优化风险分层。

核心结论

  • 脂蛋白(a)及其氧化磷脂含量与轻中度钙化性主动脉瓣狭窄的更快进展呈线性关联。
  • 该关联在多变量调整后仍具统计学显著性,支持检测脂蛋白(a)以改善管理。

研究设计与样本

  • ASTRONOMER随机临床试验的二次分析,多中心研究,加拿大23个中心。
  • 纳入220例轻中度钙化性主动脉瓣狭窄患者,峰值主动脉射流速度2.5-4.0 m/s,中位随访3.5年(IQR 2.9-4.5年)。

临床怎么用

  • 对轻中度钙化性主动脉瓣狭窄患者可检测脂蛋白(a)水平以增强风险分层和管理。

局限性

  • 本研究为随机临床试验的二次分析,样本量220例,可能存在选择偏倚。
  • 随访时间中位3.5年,长期关联未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Several studies have reported an association of levels of lipoprotein(a) (Lp[a]) and the content of oxidized phospholipids on apolipoprotein B (OxPL-apoB) and apolipoprotein(a) (OxPL-apo[a]) with faster calcific aortic valve stenosis (CAVS) progression. However, whether this association is threshold or linear remains unclear. OBJECTIVE: To determine whether the plasma levels of Lp(a), OxPL-apoB, and OxPL-apo(a) have a linear association with a faster rate of CAVS progression. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of a randomized clinical trial tested the association of baseline plasma levels of Lp(a), OxPL-apoB, and OxPL-apo(a) with the rate of CAVS progression. Participants were included from the ASTRONOMER (Effects of Rosuvastatin on Aortic Stenosis Progression) trial, a multicenter study conducted in 23 Canadian sites designed to test the effect of statin therapy (median follow-up, 3.5 years [interquartile range, 2.9-4.5 years]). Patients with mild to moderate CAVS defined by peak aortic jet velocity ranging from 2.5 to 4.0 m/s were recruited; those with peak aortic jet velocity of less than 2.5 m/s or with an indication for statin therapy were excluded. Data were collected from January 1, 2002, through December 31, 2005, and underwent ad hoc analysis from April 1 through September 1, 2018. INTERVENTIONS: After the randomization process, patients were followed up by means of echocardiography for 3 to 5 years. MAIN OUTCOMES AND MEASURES: Progression rate of CAVS as assessed by annualized progression of peak aortic jet velocity. RESULTS: In this cohort of 220 patients (60.0% male; mean [SD] age, 58 [13] years), a linear association was found between plasma levels of Lp(a) (odds ratio [OR] per 10-mg/dL increase, 1.10; 95% CI, 1.03-1.19; P = .006), OxPL-apoB (OR per 1-nM increase, 1.06; 95% CI, 1.01-1.12; P = .02), and OxPL-apo(a) (OR per 10-nM increase, 1.16; 95% CI, 1.05-1.27; P = .002) and faster CAVS progression, which is marked in younger patients (OR for Lp[a] level per 10-mg/dL increase, 1.19 [95% CI, 1.07-1.33; P = .002]; OR for OxPL-apoB level per 1-nM increase, 1.06 [95% CI, 1.02-1.17; P = .01]; and OR for OxPL-apo[a] level per 10-nM increase, 1.26 [95% CI, 1.10-1.45; P = .001]) and remained statistically significant after comprehensive multivariable adjustment (β coefficient, ≥ 0.25; SE, ≤ 0.004 [P ≤ .005]; OR, ≥1.10 [P ≤ .007]). CONCLUSIONS AND RELEVANCE: This study demonstrates that the association of Lp(a) levels and its content in OxPL with faster CAVS progression is linear, reinforcing the concept that Lp(a) levels should be measured in patients with mild to moderate CAVS to enhance management and risk stratification. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00800800.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Capoulade R, Yeang C, Chan KL, et al. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018. PMID: 30476957. doi:10.1001/jamacardio.2018.3798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。